Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Non-Current Debt (2023 - 2026)

Alto Neuroscience has reported Non-Current Debt over the past 4 years, most recently at $13.9 million for Q1 2026.

  • Quarterly results put Non-Current Debt at $13.9 million for Q1 2026, down 30.37% from a year ago — trailing twelve months through Mar 2026 was $13.9 million (down 30.37% YoY), and the annual figure for FY2025 was $16.2 million, up 57.71%.
  • Non-Current Debt reached $13.9 million in Q1 2026 per ANRO's latest filing, down from $16.2 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $20.3 million in Q3 2025 and bottomed at $6.6 million in Q3 2024.
  • Median Non-Current Debt over the past 4 years was $12.1 million (2024), compared with a mean of $13.4 million.
  • The largest annual shift saw Non-Current Debt soared 206.53% in 2025 before it tumbled 30.37% in 2026.
  • Over 4 years, Non-Current Debt stood at $9.9 million in 2023, then rose by 3.99% to $10.3 million in 2024, then soared by 57.71% to $16.2 million in 2025, then fell by 14.14% to $13.9 million in 2026.
  • Business Quant data shows Non-Current Debt for ANRO at $13.9 million in Q1 2026, $16.2 million in Q4 2025, and $20.3 million in Q3 2025.